American Society of Clinical Oncology (ASCO), shared a post on LinkedIn:
“We are proud to announce Neal Meropol MD, FASCO, as the new Principal Investigator for the ASCO Targeted Agent and Profiling Utilization Registry (TAPUR) Study. Taking the helm as TAPUR celebrates its 10th anniversary, Dr. Meropol brings decades of expertise in clinical research, academia, and health technology to this pivotal role.
His vision for the next phase of TAPUR focuses on three core pillars: expanding clinical trial access by easing the research burden on community practices with pragmatic study elements, extending TAPUR’s scope of evidence generation, and providing robust professional development opportunities for ASCO members through participation in TAPUR committees, study design, and reporting.
Join us in welcoming Dr. Meropol to this new role and read more about his strategic goals for advancing clinical research and patient care.
Read more about his vision.”